Pharvaris Hits 52-Week High Following Positive Phase 3 Trial Results

Pharvaris NV shares surged 12.4% in morning trading on September 8, 2026, reaching a session high of $43.25 and establishing a new 52-week peak. The rally follows the release of successful Phase 3 clinical trial data for the company’s hereditary angioedema (HAE) treatment, deucrictibant XR.

Clinical Efficacy in the CHAPTER-3 Study

The company announced that its CHAPTER-3 study met its primary endpoint, demonstrating a statistically significant reduction in HAE attack rates. According to the clinical results report, the treatment reduced mean monthly HAE attack rates by 83% compared to a placebo, with a p-value of less than 0.0001.

This trial is notable for its scope. CHAPTER-3 is the first prophylaxis Phase 3 study to evaluate all three types of the condition. Patients diagnosed with Type 1 or Type 2 HAE (the most common forms characterized by C1-inhibitor deficiency) saw an 87% reduction in attack rates compared to the placebo group.

Regulatory Path and Next Steps

Pharvaris intends to use these findings to facilitate upcoming regulatory filings. The company plans to use the CHAPTER-3 data to support a New Drug Application (NDA) in the United States, which is targeted for submission during the first half of 2027.

For investors and stakeholders, the data reduces risk for the company's primary pipeline candidate. The transition from clinical trial success to the regulatory submission phase is a milestone for biopharmaceutical firms, as it moves the asset closer to potential commercialization.

Understanding HAE Prophylaxis

Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling. Prophylaxis treatments, such as deucrictibant XR, are designed to be taken preventatively to reduce the frequency and severity of these attacks. By targeting an 83% reduction in monthly attack rates, Pharvaris aims to offer an oral alternative to current standards of care.